- Home
- / Cidara Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Cidara Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$13.4
2024-10-29
Market Capitalization
$94.2 M
2024-10-29
Revenue
$1.3 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 11, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 63.9M | 1.3M | ||||||||
| General and administrative expense | 8.8M | 12.7M | 12.9M | 14.1M | 16.2M | 15.9M | 18.7M | 18.5M | 18.3M | 20.6M |
| Operating expense total | 32.3M | 48.4M | 55.7M | 63.3M | 62.6M | 83.9M | 94.0M | 86.9M | 92.5M | |
| EBIT | (32.3M) | (48.4M) | (55.7M) | (63.3M) | (41.7M) | (71.8M) | (42.3M) | (29.7M) | (24.5M) | (176.1M) |
| EBIT margin, % | -38.3% | -13811.9% | ||||||||
| Interest expense | 120.0K | 271.0K | 7.0K | 629.0K | 221.0K | 262.0K | (212.0K) | 191.0K | 2.0M | 5.8M |
| Pre tax profit | (29.5M) | (22.5M) | (170.3M) | |||||||
| Income tax expense | 272.0K | 443.0K | ||||||||
| Net Income | (32.2M) | (48.2M) | (55.7M) | (59.0M) | (41.1M) | (72.1M) | (42.5M) | (29.8M) | (22.9M) | (169.8M) |
| EPS | (0.4) | (0.3) | (26.7) |